MedPath

Clinical Trial News

King Hussein Cancer Center Achieves Breakthrough with CAR-T Cell Therapy

  • The King Hussein Cancer Center (KHCC) has developed lab-engineered T-lymphocytes (CAR-T) for immunotherapy, offering a new treatment option for blood cancer patients.
  • A state-of-the-art GMP facility enables KHCC to genetically modify patient-extracted T-lymphocytes to target and eradicate cancer cells, reducing relapse rates.
  • This pioneering treatment provides hope for Jordanian and Arab patients who have exhausted other options, marking a significant advancement in cancer care.
  • KHCC is now fully equipped to independently perform CAR-T cell therapy, positioning it among the world's leading cancer centers and fostering further medical research.

Novel Therapies for Wet AMD Target Reduced Injection Burden and Broader VEGF Inhibition

  • 4D-150 gene therapy shows a nearly 90% reduction in annualized anti-VEGF injections, with stable visual acuity and CST reduction in Phase 2 interim results.
  • EYP-1901, an intravitreal tyrosine kinase inhibitor, demonstrates an 80% reduction in treatment burden and stable visual acuity over 12 months in the DAVIO 2 trial.
  • Sozinibercept, targeting VEGF-C/D in addition to VEGF-A, shows superior visual acuity compared to ranibizumab monotherapy in Phase 2b studies, with Phase 3 trials underway.
  • These advancements highlight the potential for reduced treatment burden and improved outcomes in wet AMD through diverse mechanisms of action.

Precede Bio's Liquid Biopsy Shows Promise in Determining PSMA Expression in Prostate Cancer

  • Precede Bio presented data at ESMO 2024 demonstrating its liquid biopsy platform can reveal tumor PSMA expression from a blood test.
  • The blood test results showed high correlation with PSMA-PET imaging, a standard method for assessing PSMA expression.
  • The non-invasive test could optimize patient identification for PSMA-targeted therapies, especially where PSMA-PET imaging is limited.
  • Precede Bio's platform may also be applied to other targets like DLL3 and STEAP1 to inform therapy selection.

Preoperative Chemoradiotherapy Fails to Improve Survival in Gastric Cancer

  • A phase III trial (TOPGEAR) found that adding preoperative chemoradiotherapy to perioperative chemotherapy did not significantly improve overall survival in patients with resectable gastric cancer.
  • Median overall survival was similar in both groups: 46.4 months with preoperative chemoradiotherapy versus 49.4 months with perioperative chemotherapy alone.
  • Preoperative chemoradiotherapy did improve pathological outcomes, doubling the pathological complete response rate and increasing tumor downstaging compared to perioperative chemotherapy alone.
  • Real-world data shows perioperative chemotherapy (PC) is associated with improved overall survival (OS) in patients with gastric and GEJ cancer.

Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma

NCT01924819Active, Not RecruitingPhase 2
Australasian Gastro-Intestinal Trials Group
Posted 9/1/2009

Mayo Clinic Pharmacist Advocates for Evidence-Based Cannabis Discussions in Cancer Care

  • Mayo Clinic's GI oncology pharmacist reports daily inquiries about cannabis integration in cancer treatment plans, highlighting growing patient interest despite federal restrictions.
  • Federal classification of cannabis as a Schedule I substance creates significant barriers to conducting robust clinical trials, limiting evidence-based recommendations for cancer patients.
  • Healthcare providers are adapting their patient consultations to include direct discussions about cannabis use, focusing on harm reduction and safety rather than prohibition.

Nivolumab and Relatlimab Show Promise in MMR-Deficient Colon Cancer

  • A phase 2 study, NICHE-3, evaluated neoadjuvant nivolumab and relatlimab in locally advanced mismatch repair-deficient (dMMR) colon cancer patients.
  • The combination therapy demonstrated a promising pathologic response rate, defined as ≤50% residual viable tumor (RVT), exceeding the pre-defined threshold for success.
  • The study's findings suggest that neoadjuvant immunotherapy with nivolumab and relatlimab could be a beneficial strategy for patients with dMMR colon cancer.
  • Safety was monitored, with treatment-related adverse events assessed, and no unacceptable surgical delays were attributed to the immunotherapy regimen.

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

NCT03026140RecruitingPhase 2
The Netherlands Cancer Institute
Posted 3/29/2017

23andMe Therapeutics Presents Promising Phase 2 Data for Novel Cancer Therapies at ESMO 2024

  • 23andMe's 23ME-01473 showed anti-tumor activity in preclinical models of non-small cell lung cancer, supporting its ongoing Phase 1 trial.
  • 23ME-00610 demonstrated a confirmed partial response in a patient with refractory clear-cell renal-cell carcinoma in Phase 2 trials.
  • Higher tumor expression of CD200 correlated with increased clinical benefit from 23ME-00610, suggesting its potential as a patient selection biomarker.
  • Data suggests 23ME-00610 may benefit patients with 'cold' tumors unresponsive to PD-1/PD-L1 checkpoint inhibitors.

Study of 23ME-01473 in Patients With Advanced Solid Malignancies

NCT06290388TerminatedPhase 1
23andMe, Inc.
Posted 3/7/2024

Dupilumab Set to Revolutionize COPD Treatment, Offering New Hope for Patients

  • Dupilumab has demonstrated significant improvements in COPD symptoms, reducing breathlessness and chest infections by a third compared to existing treatments.
  • UK drug safety officials have approved dupilumab for private use, with NHS approval anticipated within the year, marking a potential major advancement in COPD care.
  • The drug, administered intravenously every two weeks, targets interleukin-4 and interleukin-13, key proteins linked to harmful inflammation in COPD patients.
  • Studies show dupilumab improves lung function and quality of life, offering a new add-on therapy alongside existing medications for uncontrolled COPD.

Study Reveals Quality Gap in Online Psoriasis Treatment Information Sources

  • A comprehensive analysis of Google search trends shows adalimumab dominates public interest in psoriasis treatments, with users primarily seeking information about technical details and costs.
  • Commercial and government websites provide the highest quality information about psoriasis treatments, scoring over 3 out of 4 points on JAMA benchmark criteria.
  • Academic and medical practice websites demonstrate lower visibility and quality scores, highlighting a need for improved online presence and content development in professional medical sources.

ONL-1204 Shows Promise in Phase 2 Trial for Rhegmatogenous Retinal Detachment

  • Phase 2 trial of ONL-1204, a novel FAS inhibitor, shows potential as an adjunctive treatment for rhegmatogenous retinal detachment (RRD).
  • The study randomized patients with RRD to two doses of ONL-1204 or sham, alongside standard surgical repair, with treatment administered via intravitreal injection.
  • While the primary endpoint of contrast sensitivity was similar across groups, ONL-1204 demonstrated visual benefit in patients at higher risk of vision loss, especially those with macula-off RRD for over 8 days.
  • Further subgroup analyses and discussions with the FDA are planned to inform the design of future clinical trials for ONL-1204 in RRD.

Trending News

1

Lundbeck's Eptinezumab Shows Strong Efficacy in Asian Chronic Migraine Patients in Phase III SUNRISE Trial

3 days ago
2

Lilly's Once-Weekly Insulin Efsitora Alfa Achieves Non-Inferiority in Phase 3 Trials, Reducing Injection Burden by 300 Doses Annually

2 days ago
3

Otsuka Pharmaceutical Secures Global Rights to HBM7020 BCMAxCD3 Bispecific T-Cell Engager for Autoimmune Diseases

a day ago
4

Japanese Startup's Urine-Based Cancer Test Detects Stage 0 Lung Cancer in Hokkaido Pilot Study

2 days ago
5

Novo Nordisk's Mim8 Shows Safe Direct Switch from Emicizumab in Phase 3b Hemophilia A Trial

2 days ago
6

Roche's NXT007 Achieves Zero Bleeds in Phase I/II Hemophilia A Trial, Advances to Phase III

a day ago
7

EMA Recommends Approval of Alvotech's Biosimilar to Eylea for Eye Disorders

a day ago
8

AltruBio's ALTB-268 Shows Promise in Preclinical Models of Inflammatory Diseases, Supporting Phase 2 UC Trial

a day ago
9

XtalPi Secures $100 Million Partnership with Harvard's Gregory Verdine to Advance AI-Driven Drug Discovery

2 days ago
10

BioNxt Launches Feasibility Study for Oral Dissolvable Film Semaglutide Delivery

a day ago
Subscribe Icon

Daily Pharma Insights

Get curated, high-impact pharmaceutical news delivered to your inbox every morning.

  • Critical clinical trial updates & results
  • Regulatory approvals & strategic partnerships
  • Market access decisions & commercial developments
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy